Article

Medical therapy may be better option after PNL

San Francisco--Second-look nephroscopy following percutaneous nephrolithotomy (PNL) could be supplanted by metabolic evaluation and aggressive medical therapy, said researchers from the Duke University Medical Center. Second-look nephroscopy is currently the gold standard for assessing and achieving stone-free status, but the Duke researchers sought to determine whether this additional procedure was necessary.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
Study links poor semen quality with shorter life span
March 5th 2025

Study links poor semen quality with shorter life span

Hannah Clarke
The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
March 4th 2025

UTUC roundtables: Grade and location drive care

Urology Times staff
In 2 recent case-based roundtable discussions, experts tackled diagnosis and treatment strategy for upper tract urothelial carcinoma.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies
March 3rd 2025

FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies

Hannah Clarke
The FDA is requiring a warning about increased blood pressure and is recommending that the black box warning related to the increased risk of adverse cardiovascular events be removed.
FDA updates in urology: February 2025
March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
© 2025 MJH Life Sciences

All rights reserved.